11.04.2017
MorphoSys AG DE0006632003
DGAP-News: MorphoSys to Present at Upcoming Conferences
DGAP-News: MorphoSys AG / Key word(s): Conference
MorphoSys to Present at Upcoming Conferences (news with additional features)
11.04.2017 / 14:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, April 11, 2017
MorphoSys to Present at Upcoming Conferences
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will
present at the following conferences:
10th Kempen Life Sciences Conference
Date: April 19, 2017
Venue: Amsterdam, Netherlands
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
UBS Global Healthcare Conference
Date: May 22/23, 2017
Venue: New York, NY, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Berenberg European Conference
Date: May 24, 2017
Venue: Tarrytown, NY, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
A PDF version of the presentation will be provided at www.morphosys.com.
The Annual General Meeting of MorphoSys AG will take place on May 17, 2017
in Munich. A live webcast of the event and all related information are
available on www.morphosys.com/agm.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in the pharmaceutical industry. By successfully applying this and other
patented technologies, MorphoSys has become a leader in the field of
therapeutic antibodies, one of the fastest-growing drug classes in human
healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment
of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a
few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit
http://www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R),
Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R)
and LanthioPep(R) are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve risks and uncertainties. Should actual conditions differ from
the Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these
forward-looking statements as far as the wording of the relevant press
release is concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=YVRIABWIXH
Document title: Media Release
---------------------------------------------------------------------------
11.04.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
564083 11.04.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR